Cargando…

Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis

Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Widhani, Alvina, Hasibuan, Anshari Saifuddin, Rismawati, Retia, Maria, Suzy, Koesnoe, Sukamto, Hermanadi, Muhammad Ikrar, Ophinni, Youdiil, Yamada, Chika, Harimurti, Kuntjoro, Sari, Aldean Nadhyia Laela, Yunihastuti, Evy, Djauzi, Samsuridjal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535431/
https://www.ncbi.nlm.nih.gov/pubmed/37766132
http://dx.doi.org/10.3390/vaccines11091456
_version_ 1785112628009369600
author Widhani, Alvina
Hasibuan, Anshari Saifuddin
Rismawati, Retia
Maria, Suzy
Koesnoe, Sukamto
Hermanadi, Muhammad Ikrar
Ophinni, Youdiil
Yamada, Chika
Harimurti, Kuntjoro
Sari, Aldean Nadhyia Laela
Yunihastuti, Evy
Djauzi, Samsuridjal
author_facet Widhani, Alvina
Hasibuan, Anshari Saifuddin
Rismawati, Retia
Maria, Suzy
Koesnoe, Sukamto
Hermanadi, Muhammad Ikrar
Ophinni, Youdiil
Yamada, Chika
Harimurti, Kuntjoro
Sari, Aldean Nadhyia Laela
Yunihastuti, Evy
Djauzi, Samsuridjal
author_sort Widhani, Alvina
collection PubMed
description Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of developing COVID-19. Using a systematic review and meta-analysis, this research sought to summarize the evidence on COVID-19 vaccine efficacy, immunogenicity, and safety in patients with autoimmune diseases following predefined eligibility criteria. Research articles were obtained from an initial search up to 26 September 2022 from PubMed, Embase, EBSCOhost, ProQuest, MedRxiv, bioRxiv, SSRN, EuroPMC, and the Cochrane Center of Randomized Controlled Trials (CCRCT). Of 76 eligible studies obtained, 29, 54, and 38 studies were included in systematic reviews of efficacy, immunogenicity, and safety, respectively, and 6, 18, and 4 studies were included in meta-analyses for efficacy, immunogenicity, and safety, respectively. From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. They also had more local and systemic adverse events after the first dose of inactivated vaccination compared with healthy controls. After COVID-19 mRNA vaccination, patients with autoimmune diseases had lower TAb titers and IgG seroconversion compared with healthy controls.
format Online
Article
Text
id pubmed-10535431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105354312023-09-29 Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis Widhani, Alvina Hasibuan, Anshari Saifuddin Rismawati, Retia Maria, Suzy Koesnoe, Sukamto Hermanadi, Muhammad Ikrar Ophinni, Youdiil Yamada, Chika Harimurti, Kuntjoro Sari, Aldean Nadhyia Laela Yunihastuti, Evy Djauzi, Samsuridjal Vaccines (Basel) Systematic Review Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of developing COVID-19. Using a systematic review and meta-analysis, this research sought to summarize the evidence on COVID-19 vaccine efficacy, immunogenicity, and safety in patients with autoimmune diseases following predefined eligibility criteria. Research articles were obtained from an initial search up to 26 September 2022 from PubMed, Embase, EBSCOhost, ProQuest, MedRxiv, bioRxiv, SSRN, EuroPMC, and the Cochrane Center of Randomized Controlled Trials (CCRCT). Of 76 eligible studies obtained, 29, 54, and 38 studies were included in systematic reviews of efficacy, immunogenicity, and safety, respectively, and 6, 18, and 4 studies were included in meta-analyses for efficacy, immunogenicity, and safety, respectively. From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. They also had more local and systemic adverse events after the first dose of inactivated vaccination compared with healthy controls. After COVID-19 mRNA vaccination, patients with autoimmune diseases had lower TAb titers and IgG seroconversion compared with healthy controls. MDPI 2023-09-04 /pmc/articles/PMC10535431/ /pubmed/37766132 http://dx.doi.org/10.3390/vaccines11091456 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Widhani, Alvina
Hasibuan, Anshari Saifuddin
Rismawati, Retia
Maria, Suzy
Koesnoe, Sukamto
Hermanadi, Muhammad Ikrar
Ophinni, Youdiil
Yamada, Chika
Harimurti, Kuntjoro
Sari, Aldean Nadhyia Laela
Yunihastuti, Evy
Djauzi, Samsuridjal
Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
title Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
title_full Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
title_fullStr Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
title_full_unstemmed Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
title_short Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
title_sort efficacy, immunogenicity, and safety of covid-19 vaccines in patients with autoimmune diseases: a systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535431/
https://www.ncbi.nlm.nih.gov/pubmed/37766132
http://dx.doi.org/10.3390/vaccines11091456
work_keys_str_mv AT widhanialvina efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT hasibuanansharisaifuddin efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT rismawatiretia efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT mariasuzy efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT koesnoesukamto efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT hermanadimuhammadikrar efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT ophinniyoudiil efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT yamadachika efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT harimurtikuntjoro efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT sarialdeannadhyialaela efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT yunihastutievy efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis
AT djauzisamsuridjal efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis